Kornimate/medical-research-clean huggingface dataset:
validation of capillary serum sodium levels

Conditions: Nocturia

Summary: prospective interventional study to determine sodium levels in capillary blood via finger prick. the goal is to determine if this technique is suitable and equal to a standard venous blood collection for the analysis of blood sodium levels.the purpose is to compare both sodium levels to determine if they are equal so the technique can be used in a clinical setting for people who need regular blood collections for the determination of sodium, for example after the start of desmopressin use.

currently, serum sodium levels are determined by standard venous blood sampling. this method is invasive, painful and a relatively large amount of blood is drawn (5ml). repeated blood draws are necessary in certain patient groups. if sodium values can be determined on a capillary blood sample instead of a classic venous blood sample, the total blood volume will be smaller. in addition, in the future, the aim is to perform capillary blood sampling at home and to send the sample by courier, thus saving the patient a trip to the doctor's office or a nurse at home. the aim of this prospective interventional study is to validate the sodium values on a capillary blood sample obtained via fingerstick (250µl). to demonstrate that the obtained values are reliable and clinically useful they will be compared one-on-one with the sodium values determined on a standard venous blood sample. since it is important to validate a broad range of sodium values, a heterogeneous study population is chosen to obtain sufficient variation. patients admitted to the urology department at uz gent will be informed verbally and in writing about the content and purpose of the study. if they are interested in participating, they will be asked to sign the consent form. at the moment the already planned venous blood collection, a capillary blood sample will be taken as well via a finger prick. a number of blood drops (250 µl) are collected in a standard lithium-heparin tube and will be collected by lab maenhout for further analysis. the venous blood sample, which is taken as part of the therapy/diagnosis (independent of the study, standard of care) during admission, is analyzed by the clinical lab of uz gent. the sodium values from the capillary blood draw will be compared with the values from the venous blood draw, with each patient acting as their own control. there is no need to have the venous blood samples analyzed by labo maenhout, as the clinical lab of uz gent uses the same technique for sodium determination (indirect determination) as labo maenhout. the sodium values obtained through capillary and venous blood sampling will be statistically analyzed using a passing-bablok regression model.

Eligibility criteria:
inclusion criteria: * above 18 years or older * admitted to the urology ward exclusion criteria: * none

Keywords: nocturia desmopressin hyponatremia blood chemical analysis
the effect of continuous intravenous infusion of lidocaine on ppcs and prognosis in emergency surgical patients with iai

Conditions: Postoperative Pulmonary Complications; Intra-abdominal Infection

Summary: the main purpose of this study is to evaluate the impact of continuous 24-hour intravenous infusion of lidocaine on the incidence of ppcs in patients undergoing emergency laparotomy for intra-abdominal infection (iai).the secondary objectives of this study are to assess the impact of continuous 24-hour intravenous lidocaine infusion on the proportion of patients requiring mechanical ventilation, protection of important organ function during the perioperative period, length of hospital stay, and outcomes within 30 days postoperatively.

ppcs are defined as the occurrence within 2 days postoperatively of atelectasis unplanned ventilation, acute respiratory distress syndrome (ards), and postoperative pneumonia syndrome unplanned ventilation postoperatively: defined as the use of non-invasive mechanical ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) after the first extubation postoperatively or if extubation cannot be performed as planned. acute respiratory distress syndrome (ards): defined as acute diffuse inflammatory lung injury leading to increased pulmonary vascular permeability, increased lung weight, loss of aerated lung tissue, hypoxemia, and bilateral opacities on imaging (using the berlin consensus definition). postoperative pneumonia: defined according to the diagnostic criteria in the "chinese adult hospital-acquired pneumonia and ventilator-associated pneumonia diagnosis and treatment guidelines" (2018 version): new or progressive infiltrates, consolidation, or ground-glass opacities on chest x-ray or ct, along with two or more of the following clinical symptoms: ① fever (\> 38.0°c), ② purulent respiratory secretions, ③ peripheral blood leukocyte count \> 10×10\^9/l or \< 4×10\^9/l.

Eligibility criteria:
inclusion criteria: * age \>18 years, any gender. * patients suspected of digestive tract perforation or obstruction based on physical examination, confirmed by imaging, requiring emergency surgical treatment. * the anesthesia method is general anesthesia * i or the patient's family have carefully read and signed the informed consent form * serum procalcitonin (pct) at inflammatory levels or leukocytosis (\>12×109/l) or leukopenia (\ 10% naive leukocytes exclusion criteria: * have a history of local anesthesia drug allergy * pregnant patients * patients receiving renal replacement therapy * patients with arrhythmias or heart failure (second or third-degree atrioventricular block or left ventricular ejection fraction \[lvef\] * preoperative platelet count\<80 × 109/l * patients who require secondary surgery for postoperative anastomotic fistula * patients who have participated in other clinical studies

Keywords: intra-abdominal infection lidocaine postoperative pulmonary complications
covert-saccades, dynamic visual acuity and quality of life

Conditions: Vestibular Diseases

Summary: patients with chronic bilateral vestibular hypofunction may suffer from a visual instability during head movement called oscillopsia. visual consequence of vestibular deficit can lead to a severe impairment of their quality of life. however, correcting saccades during rapid head movement, called covert-saccades, have been more recently identified. these saccades, which occur during the head movement in patients with vestibular hypofunction, present a very short latency. they could compensate for the lack of vestibular-ocular reflex and greatly decrease oscillopsia and visual impairment. the objective of this study is to evaluate the potential functional benefice of these compensatory movements in a population of 20 patients with chronic bilateral areflexia, in a cross-sectional study.


Eligibility criteria:
inclusion criteria: * bilateral vestibular hypofunction (bvh) with at least two of the tree following criteria * mean peak slow phase velocity of 5°/s or less in bilateral bithermal (30 and 44°c) caloric irrigations * pathologic head-impulse test * vor gain of \<0.25 on rotatory chair tests * disorder present for over 6 month * comprehension of the experiments instructions * patient consent exclusion criteria: * corrected visual acuity lower than 5/10 * other conditions leading to oscillopsia or ataxia * oculomotor palsy, ocular instability in primary position * cervical rachis pathology with instability * cochlear implants * non-stabilized medical disease * pregnant women * patients under tutelage

Keywords: bilateral vestibular hypofunction video head impulse test covert-saccades quality of life dynamic visual acuity
standardizing emergency work-ups around risk data

Conditions: Acute Coronary Syndrome; Chest Pain; Risk Reduction

Summary: chest pain is the second leading reason for emergency department (ed) visits in the united states. resource utilization for this ed subpopulation is particularly high, in part due to a dearth of accepted standardized clinical approaches and general overestimation of risk on the part of both providers and patients. this prospective observational cohort study seeks to address this issue by providing externally validated risk scores for major adverse cardiac events using a web-based clinical decision support platform (ristra) embedded within the electronic health record at 13 kaiser permanente northern california (kpnc) eds over a 12-month period. the decision support will provide risk estimates specific to the kpnc patient population. this studies hypothesis is that the provision of more accurate risk estimation for major adverse cardiac events will improve informed decision making by both providers and patients, resulting in less provocative testing and lower ed lengths of stay amongst low risk patients, as well as improving medical management among non-low risk patients and decreasing future rates of major adverse cardiac events.


Eligibility criteria:
inclusion criteria: * emergency department chief complaint of chest pain or chest discomfort * clinical concern for possible cardiac ischemia
management of severe congenital blepharoptosis

Conditions: Blepharoptosis

Summary: frontalis sling surgery was carried out using ptose-up under general anaesthesia for patients with severe congenital ptosis.

frontalis sling surgery was carried out using ptose-up for patients with severe congenital ptosis in 23 eyes of 15 patients and they followed up for at least 6 months to detect the success rate and if there is any postoperative complications.

Eligibility criteria:
inclusion criteria: * severe congenital blepharoptosis * poor levator muscle function * no previous ptosis surgery exclusion criteria: * patients with jaw winking phenomenon * blepharophimosis syndrome * congenital myasthenia
seattle spatial transcriptomic research in inflammatory bowel disease evaluation (stride)

Conditions: Inflammatory Bowel Diseases; Crohn Disease; Ulcerative Colitis; Indeterminate Colitis; Functional Abdominal Pain Syndrome; Functional Bowel Disorder; Esophageal Diseases; Gastroduodenal Disorder; Bowel Dysfunction; Gallbladder Diseases; Sphincter of Oddi Dysfunction; Anorectal Disorder

Summary: this is a prospective observational study collecting long-term clinical data and samples for research in pediatric inflammatory bowel disease (ibd) patients with gut inflammation and a control cohort of pediatric patients with disorders of the brain-gut interactions (dbgi) with no detectable gut inflammation.

research procedures will coincide with clinical visits at institutional standards. as part of their clinical disease evaluation, participants will have blood, stool, and tissue collected as indicated by their disease course. additional research samples or data will be collected during these visits. participants will be asked to collect urine samples specifically for research.

Eligibility criteria:
inclusion criteria: * suspected diagnosis of cd (crohn's disease), uc (ulcerative colitis) or indeterminate colitis (ic) exclusion criteria: * evidence of other complicating medical issues: * other serious medical conditions, such as neurological, liver, kidney, or systemic disease * pregnancy * tobacco, alcohol, or illicit drug abuse

Keywords: ibd dgbi
elimination of hepatitis c virus among users of substances

Conditions: Hepatitis C in Substance Users

Summary: substance users are a vulnerable group that should be prioritized in hcv (hepatitis c virus) elimination efforts in mexico and in which it is feasible to carry out micro-elimination programs. it is an important group to treat both because of its high prevalence and because of the dynamic spread of infection among the general population. hcv seropositivity has not been documented in this group of people in mexico city, the metropolitan area and the northern states of the country, nor has the sustained viral response been evaluated in this group of patients in the mexican population.

the investigators would use a work team, the program and the value proposal would be presented to the local authorities, the coordinator of the national commission against dependencies and doctors. the investigators would use an algorithm designed for the first-step diagnosis of hcv in sus (substances users) , and defined the key centers for screening and linking to care. the project is planned as follows: * screening: sus in centers of substance users in mexico city, the metropolitan area and states in the north of the country will be evaluated with rapid tests. those with a positive result will be selected. * diagnosis: patients with a positive rapid test result will undergo a viral load test against hcv. those with positive results will be selected. * link-up: those who are confirmed positive will be profiled to receive treatment at incmnsz. they will receive damage reduction to prevent reinfection or primary infection in negatives (granted by the rehabilitation center). * treatment: the treatment will be received in a certified hospital (incmnsz) to treat patients with hcv infection, the treatment will be indicated by doctors who work in this hospital in the treatment consultations for hepatitis c or in centers with substance users with doctors trained to administer the treatment. this training will be received by telementoring. and also during the treatment, follow-up will be given with telementoring sessions if necessary. this group of people has personality characteristics that require a integral treatment, so it will be a integral and multidisciplinary treatment with psychological care and harm reduction (provided by the rehabilitation center) * confirm svr: a viral load test will be performed 12 weeks after the end of treatment to corroborate svr. they will be given after this a mentorship for harm reduction and advice against reinfections the importance of this project is characterized by minimal monitoring, patients and doctors education by telementoring, multidisciplinary teams and integral treatment

Eligibility criteria:
inclusion criteria: * patients older than 18 years. * active infection by hepatitis c virus. * people who use substances and who are users of rehabilitation centers in mexico city, the metropolitan area and the northern states of the country. * signature of informed consent exclusion criteria: * all those who do not fit the inclusion criteria

Keywords: hcv elimination substance users
peroxisomal defects and familial risk for bipolar disorder

Conditions: Bipolar Disorder; Mania

Summary: the purpose of this study is to screen for peroxisome defects in child and adolescent offspring of bipolar disorder i (bd-i) parents at different stages of risk for transitioning to mania and following the onset of mania. prediction 1: youth with an elevated risk for developing bd-i and first-episode manic patients will exhibit graded deficits in measures of peroxisomal function compared with healthy controls. prediction 2: indices of peroxisomal function will be correlated with red blood cells docosahexaenoic acid (dha) composition. prediction 3: graded deficits in measures of peroxisomal function will be inversely correlated with manic and depression symptom severity scores.

overall study design: this study entails collecting fasting venous blood (20 ml) from, and administering the 'omega-3 questionnaire' to, subjects being recruited from ongoing national institute of mental health (nimh)-sponsored trials within the department of psychiatry, university of cincinnati college of medicine. specifically, blood will be collected from 20 healthy controls (i.e., no personal or family history of any axis i mood disorder according to the diagnostic and statistical manual of mental disorders-iv \[dsm-iv\]) and 20 asymptomatic high-risk (i.e., have a biological parent with bd-i) adolescents (aged 10-18 years old) recruited for study mh077138 (uc-irb #: 07-04-10-03, bitrec project 3; pi: delbello), 20 ultra-high risk (i.e., have a biological parent with bd-i and a major depressive disorder (mdd) diagnosis) recruited for study mh083924 (uc-irb #: 04-09-15-03, co-principal investigators delbello/mcnamara), and 20 adolescents who are admitted for their first hospitalization and who have a diagnosis of bd-i recruited for study mh080973 (uc-irb #: 08-10-30-01, principal investigator: delbello). blood will then be processed, and de-identified tubes sent to the kennedy krieger institute, peroxisomal diseases section, to determine the following measures of peroxisomal function: (1) plasma very long chain fatty acids (c24:0 \& c26:0) concentrations, (2) plasma bile acid c27 intermediate (dehydrocrepenynic acid {dhca},tetrahydrocannabinolic acid {thca})concentrations, (3) plasma pipecolic acid concentrations, and (4) red blood cell (rbc) plasmalogen concentrations. additionally, rbc fatty acid composition will be determined by gas chromatography, and platelet function and plasma inflammatory markers assayed using commercially available kits according to manufacturer's instructions.

Eligibility criteria:
subject characteristics: all subjects will be 10-18 year old males and females. up to 80 patients will be enrolled in this study. subjects will be screened according to previously approved individual study criteria (uc-irb #: 07-04-10-03; 04-09-15-03; 08-10-30-01). inclusion criteria: * 10 -18 year old males \& females * based on currently enrolled study. exclusion criteria: * based on currently enrolled study.
informcll™: a disease registry for patients with chronic lymphocytic leukemia

Conditions: Chronic Lymphocytic Leukemia (CLL)

Summary: the study is designed as a multicenter, prospective, observational registry of cll/sll patients who are initiating approved oral kinase inhibitors, bcl-2 inhibitors or other approved anti-cll therapies/regimens. the study will characterize treatment patterns and their association with patient characteristics, healthcare resource utilization, and clinical outcomes, as well as patient-reported outcome (pro) measures.

this multicenter, prospective, observational registry of cll patients is designed to characterize and describe treatment patterns for those initiating treatment with approved oral kinase inhibitors and other approved anti-cll therapies/ regimens. the registry will provide information on regimens used to treat first-line and later lines of cll as well as the sequencing of treatment regimens. the registry will also evaluate the association of these treatment patterns with patient characteristics, healthcare resource utilization, and functional outcomes including patient-reported hrqol. these data will provide information to physicians that may help guide clinical practice and appropriate use of therapies, and will also provide information on hrqol and healthcare resource utilization that will be of interest to healthcare decision makers.

Eligibility criteria:
inclusion criteria: * age of at least 18 years * clinical diagnosis of cll/sll that meets published diagnostic criteria (hallek 2008) * initiating anti-cll/sll treatment regimen (excluding clinical trials) within ±45 days of enrollment * availability of documentation of previous cll/sll treatment and duration of response in the patient's medical records if patient has received prior line(s) of treatment (i.e. not treatment naïve) * willing and able to provide informed consent * willing and able to complete pro instrument * willing and able to provide information on patient survey questionnaire * willing and able to provide a blood sample at time of enrollment prior to receiving treatment, as possible exclusion criteria: * diagnosis of b-cell malignancies other than cll/sll * estimated life expectancy \<6 months * currently receiving treatment in an interventional clinical trial at time of entry into this study \* note- exceptions: 1) patients may enroll in interventional clinical trials for indications other than cll/sll, 2) the interventional clinical trial treatment is not the treatment used for meeting inclusion criteria #2 (or "index treatment"), 3) patients may enroll in an interventional clinical trial indicated for cll/sll as later line of treatment after discontinuing the index treatment

Keywords: chronic lymphocytic leukemia cll small lymphocytic leukemia sll
the impact of platelet function on 1-year outcome in complex pci patients

Conditions: Percutaneous Coronary Intervention; Coronary Artery Disease

Summary: to identify the optimal cut-off values in different platelet function testing to predict macce at 12-months in complex pci patients of china

this study will observe the relationship between platelet function testing and clinical outcomes. meanwhile we aim to identify optimal cut-off values in different platelet function testing, including ipf, teg and verifynow, to predict macce during12-months in complex pci patients.

Eligibility criteria:
inclusion criteria: * documented undergoing complex pci in 1 year prior to enrollment. exclusion criteria: * presence of any condition/circumstance which in the opinion of the investigator could significantly limit the complete follow up of the patient (e.g. tourist, non-native speaker or does not understand the local language where interpreter services are not reliably available, psychiatric disturbances, alcohol or drug abuse). * presence of serious/severe co-morbidities in the opinion of the investigator which may limit life expectancy (\<1 year). * current participation in a blinded randomized clinical trial.

Keywords: percutaneous coronary intervention antiplatelet platelet function prognosis
probiotic treatment of orthodontic patients

Conditions: Dental Plaque; Dental Caries

Summary: the purpose of this study is to examine the effect of treatment with a lozenge containing the probiotic strain s. salivarius m18 on the formation, composition and virulence of dental plaque and in healthy orthodontic patients, compared to placebo control.


Eligibility criteria:
inclusion criteria: 1. generally healthy males and females ≥ 10 years of age. 2. able to read and receive a copy of the signed informed consent form. 3. have at least 20 natural teeth. 4. have been undergoing orthodontic treatment with fixed orthodontic appliances in the upper and/or lower jaw \> 6 months. 5. an average plaque score of \> 2 according to the modified orthodontic plaque index (mopi) at the screening appointment. exclusion criteria: 1. significant oral soft tissue pathology based on a visual examination. 2. history of allergy or significant adverse events following use of oral hygiene products such as toothpastes, mouth rinses, breath mints, lozenges, or chewing gum or their ingredients. 3. history of allergies to milk proteins. 4. history of allergies towards probiotics. 5. self-reported as pregnant or nursing. 6. self-reported serious medical conditions. 7. antibiotic or anti-inflammatory medication within 30 days of screening visit. 8. acute sinusitis or severe oral-pharyngeal infections. 9. smoker.